Eric Davis - BioMarin Pharmaceutical Insider

BMRN -- USA Stock  

USD 95.65  2.78  2.82%

Sr. VP, General Counsel and Secretary

Mr. G. Eric Davis serves as Executive Vice President, General Counsel and Secretary of Biomarin Pharmaceutical Inc. He joined BioMarin in March 2004 and currently serves as our Executive Vice President, General Counsel and Secretary. From December 2005 to March 2016, Mr. Davis served as our Senior Vice President, General Counsel and Secretary and from 2004 to December 2005, Mr. Davis served as our Vice President, General Counsel and Secretary. From 2000 to 2004, Mr. Davis worked in the San Francisco office of Paul Hastings LLP, where he served on the firms national securities practice committee. Mr. Davis has represented public and private companies and VC and investment banking firms in a wide range of corporate and securities matters, mergers and acquisitions, strategic alliance matters, and intellectual propertyrelated business transactions. His experience involves a variety of industries, including biotechnology and life sciences
Age: 46  SVP Since 2016      
415-506-6700  http://www.biomarin.com
Davis received a B.A. in political economy from the University of California, Berkeley, and a J.D. from the University of San Francisco School of Law.

Management Efficiency

The company has return on total asset (ROA) of (2.1) % which means that it has lost $2.1 on every $100 spent on asset. This is way below average. Similarly, it shows return on stockholders equity (ROE) of (5.2) % meaning that it created substantial loss on money invested by shareholders.
The company currently holds 1.18 B in liabilities with Debt to Equity (D/E) ratio of 42.1 indicating the company may have difficulties to generate enough cash to satisfy its financial obligations. BioMarin Pharmaceutical has Current Ratio of 2.84 suggesting that it is liquid enough and is able to pay its financial obligations when they are due.

Similar Executives

Found 6 records

SVP Since

Frank ScholzMallinckrodt Public Limited Com
2018
Ian WatkinsMallinckrodt Public Limited Com
2016
John ElickerBristol Myers Squibb Company
2017
Rita KarachunMerck Co
2014
Paul AutenriedBristol Myers Squibb Company
2016
Michael HarringtonEli Lilly and Company
2013

Entity Summary

BioMarin Pharmaceutical, Inc., a biotechnology company, develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. The company was founded in 1996 and is headquartered in San Rafael, California. BioMarin Pharmaceutical operates under Biotechnology classification in USA and traded on NASDAQ. It employs 2581 people.BioMarin Pharmaceutical (BMRN) is traded on NASDAQ in USA. It is located in CALIFORNIA, U.S.A and employs 2,581 people. BioMarin Pharmaceutical is listed under Pharmaceutical Products category by Fama And French industry classification.

BioMarin Pharmaceutical Leadership Team

Elaine Heron, Director, MBA
Dennis Slamon, Director, Ph.D
Henry Fuchs, President, Ph.D
Robert Hombach, Director, MBA
Brian Mueller, VP
Bryan Lawlis, Director
JeanJacques Bienaime, Chairman, MBA
Jeff Ajer, President, MBA
Richard Meier, Director
Willard Dere, Director
Daniel Spiegelman, President, MBA
Kathryn Falberg, Director, MBA
Eric Davis, SVP
Pierre Lapalme, Chairman
Robert Baffi, EVP, MBA
Alan Lewis, Director, Ph.D
Richard Ranieri, President
David Pyott, Director, MBA
Michael Grey, Director

Stock Performance Indicators

Did you try this?

Run Performance Analysis Now
   

Performance Analysis

Check effects of mean-variance optimization against your current asset allocation
All  Next Launch Performance Analysis

Pair Correlation

Equities Pair Trading Analysis
Correlation analysis and pair trading evaluation for BioMarin Pharmaceutical and IQVIA Holdings. Pair trading can be used as a hedging technique within a particular sector or industry or even over random equities to generate better risk-adjusted return
Run Pair Correlation  
Check also Trending Equities. Please also try Equity Search module to search for activelly-traded equities including funds and etfs from over 30 global markets.